FOR US HEALTHCARE PROFESSIONALS ONLY

FOR US HEALTHCARE PROFESSIONALS ONLY

REQUEST A REP

Guidance for ongoing monitoring

After prescribing DUVYZAT, monitor patients in the first year as follows:

Month 1 2 3 4 5 6 7 8 9 10 11 12
CBC +
Differential

Every 2 weeks
Triglycerides

Triglycerides

CBC + Differential

CBC + Differential

Monitor blood counts every 2 weeks for the first 2 months of treatment, at month 3, and then every 3 months thereafter

CBC, complete blood count.

Triglycerides

Monitor triglycerides at 1 month, 3 months, 6 months, and then every 6 months thereafter

After the first 3 months of treatment with DUVYZAT, your patient's blood monitoring will become less frequent.

Additional guidance for ongoing monitoring

  • Closely monitor patients when DUVYZAT is used in combination with an oral CYP3A4 sensitive substrate or a sensitive substrate of the OCT2 transporter, for which a small change in substrate plasma concentration may lead to serious toxicities
  • Avoid concomitant use with other drugs that prolong the QTc interval
  • Monitor ECG if concomitant use cannot be avoided

ARs, adverse reactions.

Adjusting dosage for adverse reactions

Dosing modifications are available to manage ARs for patients currently taking DUVYZAT.

SEE DOSING MODIFICATIONS

Get started with DUVYZAT

Download and complete this form to get your patients started with DUVYZAT with the help of ITF ARC. ACCESS THE FORM

Sign up for updates

Get valuable resources, patient support tools, and information delivered directly to you. SIGN UP

References: 1. DUVYZAT. Prescribing information. ITF Therapeutics; 2024. 2. Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al; EPIDYS Study Group. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393-403.

Indication and Important Safety Information

DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

Important Safety Information

Warnings and precautions

  • Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression, including anemia and neutropenia. Monitor platelets; dosage adjustment or discontinuation may be needed.
  • Increased Triglycerides: An increase in triglycerides can occur; dosage modification may be needed. Discontinuation may be needed.
  • Gastrointestinal Disturbances: Adjust dosage if moderate or severe diarrhea occurs. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Discontinue DUVYZAT if the symptoms persist.
  • QTc Prolongation: Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias.

Indication

DUVYZAT is a histone deacetylase inhibitor indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.

Important Safety Information

Warnings and precautions

  • Hematological Changes: DUVYZAT can cause dose-related thrombocytopenia and other signs of myelosuppression, including anemia and neutropenia. Monitor platelets; dosage adjustment or discontinuation may be needed.
  • Increased Triglycerides: An increase in triglycerides can occur; dosage modification may be needed. Discontinuation may be needed.
  • Gastrointestinal Disturbances: Adjust dosage if moderate or severe diarrhea occurs. Antiemetics or antidiarrheal medications may be considered during treatment with DUVYZAT. Discontinue DUVYZAT if the symptoms persist.
  • QTc Prolongation: Avoid use of DUVYZAT in patients who are at an increased risk for ventricular arrhythmias.

Recommended Evaluation and Testing Before Initiation of DUVYZAT:

Obtain and evaluate baseline platelet counts and triglycerides prior to initiation of DUVYZAT. Do not initiate DUVYZAT in patients with a platelet count less than 150 x 109/L. Monitor platelet counts and triglycerides as recommended during treatment to determine if dosage modifications are needed.

In addition, in patients with underlying cardiac disease or taking concomitant medications that cause QT prolongation, obtain ECGs when initiating treatment with DUVYZAT, during concomitant use, and as clinically indicated.

Most Common Adverse Reactions:

Most common adverse reactions (≥10% in DUVYZAT-treated patients) are diarrhea, abdominal pain, thrombocytopenia, nausea/vomiting, hypertriglyceridemia, and pyrexia.

To report SUSPECTED ADVERSE REACTIONS, contact ITF Therapeutics LLC at 1-833-582-4312 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information and Medication Guide.